The present invention relates to lower dosage strength pernasal testosterone gel formulations for intranasal administration and treatment methods for using the lower dosage strength pernasal testosterone gel formulations for treating a female subject with anorgasmia and/or hypoactive sexual desire disorder.

The process comprises combining prepared β-cyclodextrin solution and prepared ethinyl estradiol solution, then removing the solvent by spray-drying for obtaining an ethinyl estradiol β-cyclodextrin complex. The obtainable amorphous ethinyl estradiol β-cyclodextrin complex is suitable for use in pharmaceutical compositions and formulations comprising it.

The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.

Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.

Disclosed is a hot flash-mitigating agent that is highly effective in mitigating hot flashes associated with premenstrual syndrome. The hot flash-mitigating agent contains mallow extract as an active ingredient.

The present invention is directed to methods for treating or ameliorating skin conditions, diabetic conditions, cardiovascular conditions, cancer, infections or metal poisoning, enhancing performance, or providing nutritional support, comprising administering to a subject in need thereof compositions comprising a magnetic dipole stabilized solution (MDSS). The MDSS solution may include additional components and can be provided in a kit.

Studies in female mice lacking ovaries (and thus estrogen), and placed on a high fat diet (60% fat) to induce severe obesity, and then stimulated with a low level of high pressure stress on the heart to induce mild hypertrophy and activate natriuretic peptide signaling. Unlike females on the same diet and heart stress but with their ovaries, those without ovaries demonstrated marked weight loss from phosphodiesterase E-9 (PDE9) inhibition, in combination with improvement in their metabolic signature (reduced fasting glucose, cholesterol, and triglycerides), without any change in food intake, nor change in activity. Thus, in one aspect, the invention provides methods for decreasing body fat and increasing lean muscle mass in estrogen deficient obese female subjects comprising administering to the subjects, at least one PDE9 inhibitor.

This disclosure describes studies undertaken to determine the effectiveness of administration of low dose progesterone monotherapy in alleviating symptoms associated with menopause transition. It is apparent based on initial results that treatment with a low dose progesterone agent alleviates symptoms in many women transitioning into menopause. Progesterone at 25 mg once or twice per day can improve the quality of life for the woman in the early and late phases of menopause without side effects and no risks. Accordingly, this disclosure describes methods for treating one or more symptoms of menopause in a subject. The methods can include administering to a subject who would benefit from such treatment (e.g., a perimenopausal female) a low therapeutically effective amount of a progesterone agent to treat the subject for the one or more symptoms of menopause.

This disclosure describes studies undertaken to determine the effectiveness of administration of low dose progesterone monotherapy in alleviating symptoms associated with menopause transition. It is apparent based on initial results that treatment with a low dose progesterone agent alleviates symptoms in many women transitioning into menopause. Progesterone at 25 mg once or twice per day can improve the quality of life for the woman in the early and late phases of menopause without side effects and no risks. Accordingly, this disclosure describes methods for treating one or more symptoms of menopause in a subject. The methods can include administering to a subject who would benefit from such treatment (e.g., a perimenopausal female) a low therapeutically effective amount of a progesterone agent to treat the subject for the one or more symptoms of menopause.

Provided herein are compounds, such as compounds of Formula I, that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions. ##STR00001##